Milestone PharmaceuticalsMIST -2.16%26 Receivables Turnover is 0.15 as of Mar. 2026. GuruFocus rates MIST with a GF Score™ of 26/100. The stock has 6 warning signs investors should review. Among 839 Biotechnology companies, Milestone Pharmaceuticals ranks worse than 90.58% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Milestone Pharmaceuticals's Revenue for the
three
months ended in Mar. 2026 was $0.24 Mil. Milestone Pharmaceuticals's average Accounts Receivable for the
three
months ended in Mar. 2026 was $1.61 Mil.
Hence, Milestone Pharmaceuticals's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.15.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Milestone Pharmaceuticals Receivables Turnover Related Terms
Milestone Pharmaceuticals Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIST vs TNYA, TLSA, NRXP: Receivables Turnover Comparison
For the Biotechnology subindustry, Milestone Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Milestone Pharmaceuticals Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Milestone Pharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Milestone Pharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Milestone Pharmaceuticals (MIST) has a Receivables Turnover of 0.15 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Milestone Pharmaceuticals and its competitors. According to the industry distribution chart, Milestone Pharmaceuticals ranks #760 out of 839 companies in the Biotechnology industry, placing it in the top 90.6%.
Is Milestone Pharmaceuticals' Receivables Turnover too high?
Milestone Pharmaceuticals' current Receivables Turnover is 0.15. The Biotechnology industry median Receivables Turnover is 5.27. Milestone Pharmaceuticals' value of 0.15 is 97.2% below this industry median. Based on the distribution chart, Milestone Pharmaceuticals ranks #760 out of 839 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Milestone Pharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Milestone Pharmaceuticals' Receivables Turnover compare to TNYA and TLSA?
According to the Biotechnology industry distribution chart, Milestone Pharmaceuticals ranks #760 out of 839 companies for Receivables Turnover. This places Milestone Pharmaceuticals in the lower half of its industry. The industry median Receivables Turnover is 5.27. Milestone Pharmaceuticals' value of 0.15 is 97.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Milestone Pharmaceuticals's current Receivables Turnover of 0.15 is 97.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Milestone Pharmaceuticals and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Milestone Pharmaceuticals's current Receivables Turnover is 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Milestone Pharmaceuticals stock overvalued right now?
Milestone Pharmaceuticals (MIST) has a current Receivables Turnover of 0.15. The current Receivables Turnover is 0.15 and 97.2% below the Biotechnology industry median of 5.27. Milestone Pharmaceuticals' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Milestone Pharmaceuticals (MIST), the current Receivables Turnover is 0.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
26GF Score
Get the complete analysis for MIST
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIST has been successfully added to your 
